Clinical trial
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat…
NCT00226668 · Celtic Pharma Development Services, Industry · Withdrawn
Key facts
| NCT number | NCT00226668 |
|---|---|
| Title | XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema |
| Official title | A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma |
| Lead sponsor | Celtic Pharma Development Services, Industry |
| Collaborators | Neurobiological Technologies Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Brain Edema, Brain Tumor |
| Intervention type | Drug |
| Interventions | hCRF, placebo hCRF |
| Enrollment | 120 |
| Start date | Jan 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Sep 27, 2005 |
| Last update posted | Jan 3, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: